Observational studyClinical cardiology2017
Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.
Observational study in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Prognostic value of hemoglobin, albumin, lymphocyte, platelet (HALP) scores in patients with non-valvular atrial fibrillation: insights from the AFTER-2 study.BMC cardiovascular disorders · 2025Observational
- Mean Platelet Volume as a Predictor of Left Atrial Appendage Thrombus Resistance to Lysis in Patients With Atrial Fibrillation: Results of a 12-Month Follow-Up.Reviews in cardiovascular medicine · 2025Article
- Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center.Cureus · 2025Article
- LncRNA SERPINB9P1 expression and polymorphisms are associated with ischemic stroke in a Chinese Han population.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Cellular Immune Signal Exchange From Ischemic Stroke to Intestinal Lesions Through Brain-Gut Axis.Frontiers in immunology · 2022Review
- Low antithrombin levels are associated with low risk of cardiovascular death but are a risk factor for cancer mortality.PloS one · 2022Article
- The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes.Endocrine connections · 2021Article
- Effect of new oral anticoagulants on platelet indices in non-valvular atrial fibrillation patients.Herz · 2021Article
- A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.Frontiers in cardiovascular medicine · 2021Review
- Mean platelet volume: a new predictor of ischaemic stroke risk in patients with nonvalvular atrial fibrillation.BMC cardiovascular disorders · 2020Article
- Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies.Frontiers in medicine · 2020Review
- Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.Clinical cardiology · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCHADS HYPOTHESIS: To determine the association of antithrombin III (AT-III) deficiency and mean platelet volume (MPV) with the development of stroke or left atrial (LA) thrombus in patients with AF.
methodsAT-III and MPV were analyzed in 352 patients with AF. The primary endpoint was a composite of ischemic stroke event and incidental LA thrombus.
resultsThere were 50 events (14.2%) during a mean 35.4 months of follow-up. A significantly higher stroke or LA thrombus rate was observed in the low-AT-III group (<70%) than that in the high-AT-III group (≥70%). A significantly higher stroke or LA thrombus rate was observed in the high-MPV group (≥7.0 fL) than that in the low-MPV group (<7.0 fL). AF patients with an MPV ≥7.0 fL and AT-III deficiency had higher stroke or LA thrombus risk than those without an MPV ≥7.0 fL and AT-III deficiency. In the Cox proportional hazard analysis, high MPV was found to be an independent predictor of stroke or LA thrombus risk (hazard ratio: 6.408; 95% confidence interval: 2.874-14.286). Although AT-III deficiency was not an independent predictor of stroke or LA thrombus risk, a trend was observed.
conclusionsHigh MPV and AT-III deficiency were predictive markers for stroke or LA thrombus. Their predictive power for stroke was independent of antiplatelet treatment, anticoagulation therapy, and a high CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.